Sage Therapeutics Inc (FRA:SG7)
€ 5.452 0.102 (1.91%) Market Cap: 325.18 Mil Enterprise Value: -211.07 Mil PE Ratio: 0 PB Ratio: 0.61 GF Score: 49/100

SAGE Therapeutics Inc KINETIC Study Topline Results Conference Call Transcript

Apr 12, 2021 / 12:00PM GMT
Release Date Price: €61.92 (-3.07%)
Operator

Good morning. Welcome to Sage Therapeutics conference call to discuss the results of the KINETIC study. (Operator Instructions)

This call is being webcast live on the Investors and Media section of Sage's website at sagerx.com. This call is property of Sage Therapeutics, and recordings, reproduction and transmission of this call without expressed written consent of Sage Therapeutics is strictly prohibited. Please note, this call is being recorded.

I would now like to introduce Jeff Boyle, Vice President, Investor Relations at Sage.

Jeff Boyle
Sage Therapeutics, Inc. - Investor Contact

Good morning, and thank you for joining Sage Therapeutics conference call to discuss results from the KINETIC study with SAGE-324 in essential tremor. Before I begin, I encourage everyone to go to the Investors and Media section of our website at sagerx.com, where you can find the press release related to today's call.

I'd like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot